Combination of brimonidine and timolol for topical ophthalmic use
AssigneeAllergan Sales, Inc.
InventorsChin-Ming Chang, Gary J. Beck, Cynthia C. Pratt, Amy L. Batoosingh
Life of this patent
Estimating the term…
Abstract
Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
Claims24
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of reducing the adverse events experienced by a patient taking brimonidine comprising administering twice daily to the affected eye of the patient a single composition comprising 0.2% w/v brimonidine tartrate and 0.5% w/v timolol free base, wherein said method reduces the incidence of one or more adverse events, as compared to the administration of 0.2% w/v brimonidine tartrate monotherapy three times per day.
Dependencies are inferred from the claim text.